Company / Working Capital
Xeris Biopharma Holdings, Inc. Working Capital History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$130.7M
FY2025
5-year range
$61.1M / $130.7M
FY2021-FY2025
Trend
+94.5%
vs FY2024
Sector context
#187 of 213
Health Care
What the data says
Xeris Biopharma Holdings, Inc.'s working capital of $131M is lower than 88% of companies in the Health Care sector (FY2025). Working Capital has fluctuated over the past 6 years, ranging from $61M in FY2023 to $131M in FY2025.
Based on SEC 10-K filings.
$131M in FY2025 with a 5-year CAGR of +1.1%.
Improved from $61M to $131M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +4.9%
- 5-Year CAGR
- +1.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 213This company $130.7M Sector average $934.6M
▼
-86.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +1.1%, indicating consistent growth.
- In FY2025, working capital increased 94.5% year-over-year.
- Ranks #187 out of 213 companies in the Health Care sector.
- Lowest working capital in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $130.7M | +94.5% |
| FY2024 | $67.2M | +10.1% |
| FY2023 | $61.1M | -46.0% |
| FY2022 | $113.2M | +78.1% |
| FY2021 | $63.6M | -48.7% |
| FY2020 | $124.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026